Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Vanilloid receptor | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.0977 | 0.5592 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0531 | 1 | 1 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0124 | 0.1747 | 1 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.0307 | 0.5455 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0124 | 0.1747 | 1 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.0531 | 1 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0086 | 0.0977 | 0.1791 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0124 | 0.1747 | 1 |
Schistosoma mansoni | DNA topoisomerase II | 0.0124 | 0.1747 | 1 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0124 | 0.1747 | 0.1747 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0124 | 0.1747 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 0.0977 | 0.5592 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0531 | 1 | 0.5 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0531 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0531 | 1 | 1 |
Plasmodium falciparum | DNA gyrase subunit B | 0.0531 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0307 | 0.5455 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0307 | 0.5455 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0124 | 0.1747 | 1 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.0183 | 0.2938 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0107 | 0.1409 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0124 | 0.1747 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0348 | 0.6292 | 0.6292 |
Brugia malayi | Probable DNA topoisomerase II | 0.0124 | 0.1747 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0124 | 0.1747 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0086 | 0.0977 | 0.1791 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0124 | 0.1747 | 0.3202 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0124 | 0.1747 | 1 |
Trypanosoma brucei | DNA topoisomerase ii | 0.0307 | 0.5455 | 1 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0086 | 0.0977 | 0.1791 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0086 | 0.0977 | 0.1791 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0124 | 0.1747 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0086 | 0.0977 | 0.1791 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0307 | 0.5455 | 1 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0124 | 0.1747 | 0.1747 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0124 | 0.1747 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | Agonist activity at rat TRPV1 receptor expressed in CHO cells assessed as increase in intracellular 45Ca2+ uptake after 1 hr by fluorometric analysis | ChEMBL. | 22169633 | |
Ki (functional) | = 18.9 nM | Antagonist activity at rat TRPV1 receptor expressed in CHO cells assessed as decrease in capsaicin-induced intracellular 45Ca2+ uptake after 1 hr by fluorometric analysis | ChEMBL. | 22169633 |
Ki (binding) | = 32.8 nM | Displacement of [3H]RTX from rat TRPV1 receptor expressed in CHO cells after 60 mins by scintillation counting | ChEMBL. | 22169633 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.